Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.

J Neurol · 2022 · PMC8782807 · PMID 34191081

Europe PMC DOI

hedged sentence

0.4630

closest p · 9.3× alpha

0.4630

boldest claim

The sentences

did not reach statistical significancep = 0.463not close (p > 0.1)

Efficacy Evaluation of the dose–response relationship did not reach statistical significance (one-sided p = 0.463 for a dose–response curve demonstrating efficacy only at 4 mg, Table S-1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.